Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes.
The company was founded in 1996 and is based in New York, New York.
| Country | United States |
| IPO Date | Jun 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Pablo Gerardo Legorreta |
Contact Details
Address: 110 East 59th Street New York, New York United States | |
| Website | https://www.royaltypharma.com |
Stock Details
| Ticker Symbol | RPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001802768 |
| CUSIP Number | G7709Q104 |
| ISIN Number | GB00BMVP7Y09 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pablo Gerardo Legorreta | Founder, Chairman of the Board & Chief Executive Officer |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer |
| George Wingate Lloyd | Executive Vice President of Investments & Chief Legal Officer |
| Terrance P. Coyne | Executive Vice President & Chief Financial Officer |
| Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel |
| Ashwin Pai M.D. | Executive Vice President of Investments |
| Christopher Hite | Vice Chairman & Executive Vice President |
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments & Chief Scientific Officer |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments |
| Kristin Stafford | Senior Vice President & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Dec 31, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 4 | Filing |
| Sep 30, 2024 | 4 | Filing |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 4 | Filing |